Meridian Therapeutics uses graph neural networks to predict binding affinities and prioritize compounds for rare protein misfolding diseases. Spun from UTS's Bioengineering Lab, the company is in preclinical development with two lead programs. Patent portfolio extends across multiple jurisdictions with headquarters in Sydney.